This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cells and have the potential to stimulate the immune system to fight the tumor.
The purpose of this study is to determine the safety of IDOV-Immune, how well it is tolerated, and to identify the highest dose that can be safely given. Researchers will also study how the drug behaves in the body, how the immune system responds to it, and whether it shows any signs of shrinking tumors.
Participants will receive a single intravenous (IV) infusion of IDOV-Immune and will be closely monitored for side effects and any changes in their cancer.
This study is being conducted at multiple sites in the United States and Australia.
Age ≥ 18 years.
Histologically or cytologically confirmed advanced solid tumors that have progressed despite standard therapy, or for which no standard therapy exists.
ECOG performance status ≤ 1.
Measurable disease per RECIST v1.1.
Prior treatment with an oncolytic virus.
Active or recent vaccinia virus infection or smallpox/monkeypox vaccination within 10 years.
Active uncontrolled infection requiring systemic treatment.
History of hepatitis B, hepatitis C, or HIV (unless meeting protocol-specific criteria).